Sihuan Pharmaceutical Holdings Group Ltd. Overview
Sihuan Pharmaceutical is a Hong Kong-listed, Bermuda-incorporated Chinese healthcare group that has spent a decade migrating from a policy-exposed cardio-cerebrovascular (CCV) generic drug franchise toward a "medical aesthetics + innovative drugs" dual-engine model. Its Meiyan Space platform sells the Hugel-manufactured botulinum toxin Letybo® and a growing portfolio of self-developed regenerative fillers (PLLA, PCL), hyaluronic-acid products, skin boosters and the Sylfirm X RF-microneedle device, and since FY2025 has been the group's largest revenue and profit contributor. Its innovative-drug arm comprises Xuanzhu Biopharm (2575.HK, spun off October 2025; oncology and digestive drugs) and Huisheng Biopharm (diabetes and GLP-1). A legacy portfolio of roughly 100 generic drugs, battered by volume-based procurement (VBP), is being harvested and divested. After four loss-making years, the group returned to profit in FY2025, carries a large net cash position, and trades at a modest valuation reflecting execution, governance and policy risk.
Company's own description (FY2025 Annual Results, 31 Mar 2026)
The company frames 2025 as the year it moved from a "transformation and investment period" into a "value realisation period," built around a "dual-wheel drive" of medical aesthetics and innovative drugs, with generic medicines positioned as a "cash cow." The segment note defines three reportable segments: (a) medical aesthetic products, providing non-invasive or minimally invasive aesthetic solutions spanning filling, shaping, supporting, supplementing, optoelectronic devices, body sculpting and skin care; (b) innovative medicine and other medicine; and (c) generic medicine. The stated vision is to become a leading medical aesthetics and biopharmaceutical company in China, with the 2026 plan opening a three-year strategic cycle aimed at making Sihuan a benchmark enterprise in China's medical aesthetics industry.
Business model and revenue model
| Revenue model element | FY2025 relevance | Source |
|---|---|---|
| Product sales — medical aesthetic products | RMB1,485.3m (56.7% of revenue) | FY2025 Results |
| Product sales — innovative and other medicine | RMB176.4m (6.7%) | FY2025 Results |
| Product sales — generic medicine | RMB956.3m (36.5%) | FY2025 Results |
| In-licensed distribution (agency) | Letybo® (Hugel) and Persnica™ HA (Hugel) sold under exclusive China rights; CELLBOOSTER® (Suisselle) under permanent China agency | FY2025 Results; HKEX 27 Sep 2024 |
| Out-licensing (upfront/milestones/royalties) | Bireociclib EAEU licence; Boston Oncology MENA licence (H1 2026, >US$100m potential) | FY2025 and 2026 Interim Results |
| Commercialisation partnerships | Hui You Jing via Huadong Medicine; Hui You Jia/Hui You Da via Tonghua Dongbao | FY2025 and 2026 Interim Results |
| Device + consumables | Sylfirm X device placements with recurring consumables | 2026 Interim Results |
All reported revenue is recognised from product sales at a point in time (FY2025 revenue note). There is no material subscription, service or royalty revenue in reported turnover; licensing income from out-licensing deals and hospital services are booked in "other income" (hospital services income RMB62.0m in FY2025; R&D income RMB13.2m; distribution-rights sales RMB2.8m).
Value-chain position
Sihuan is vertically integrated in its pharmaceutical businesses (R&D, API/formulation manufacturing, regulatory, commercialisation) and operates a hybrid model in aesthetics: in-licensed hero products (Letybo®, manufactured by Hugel in Korea) used as "traffic drivers," combined with self-developed, higher-margin regenerative products manufactured in-house. Meiyan Space reports three production bases globally (HKEX announcement, 30 Sep 2025). Huisheng Biopharm operates biologics capacity of approximately 25 million units annually, with Phase II capacity of approximately 100 million units planned (2026 Interim Results).
Customers and end-markets
| Customer type | Description | Evidence |
|---|---|---|
| Medical aesthetics institutions | More than 9,000 cooperating institutions across 34 provinces and 370+ cities; all industry top-500 institutions covered; 1,500 key core hospitals | 2026 Interim Results |
| Leading aesthetic chains | Deep partnerships with Mylike and Yestar; 25% of leading chain institutions contribute 75% of Letybo® sales | FY2025 Results |
| Distributors / pharmaceutical commercial companies | Primary customers for innovative and generic drugs (Xuanzhu had over 105 distributors at IPO) | Xuanzhu IPO data (etnet) |
| Hospitals (via distributors) | Anaprazole in nearly 2,500 institutions; Bireociclib 500+ hospitals; Hui You Jing 7,000+ hospitals via Huadong | 2026 Interim Results |
| Licensing partners | Huadong Medicine, Tonghua Dongbao, Boston Oncology, partners in 15 countries for Huisheng | 2026 Interim Results |
Customer concentration (material): a single customer group accounted for approximately RMB728.5m of FY2025 revenue (27.8% of total; FY2024: RMB173.6m), and RMB173.6m in H1 2026 (vs RMB213.6m in H1 2025), across the medical aesthetics and generic segments (FY2025 and 2026 Interim Results).
Independent characterisation
Sihuan is best understood as a holding company of three businesses with very different economics: (1) a high-margin, consumer-discretionary aesthetics distributor-turned-brand-owner that now generates most of group profit (FY2025 segment gross margin 79.5%, segment profit margin 55.1%); (2) a cash-consuming innovative drug portfolio that just crossed into small segment profit in H1 2026, partly helped by licensing; and (3) a structurally declining generic franchise that swung to a segment loss in H1 2026. Reported group earnings are therefore highly sensitive to mix, to one-off disposal gains, to the minority-interest split in partly owned subsidiaries, and to a punitive effective tax rate (55.6% in FY2025) caused by unrecognised losses at loss-making subsidiaries.
Strategy
Stated strategy (FY2025 Annual Results; 2026 Interim Results)
The core framing is a "medical aesthetics + innovative drugs" dual-engine drive. The 2026 interim report describes a layered model: medical aesthetics as the primary growth pillar, innovative drugs as the second growth curve, generics as a cash-flow ballast, and gradual divestment of generic and non-core assets. For 2026, management set the theme of deepening the dual-wheel drive, unleashing synergies, expanding globally and improving capital efficiency, across five directions: compliance, product, technology, globalisation and industry-chain integration.
Strategic initiatives (last 24 months)
| Initiative | Detail | Timing | Source |
|---|---|---|---|
| Full-category compliant aesthetics portfolio | Toxin + HA + regenerative + optoelectronic + boosters; company claims to be the only firm with fully compliant coverage of all non-invasive categories | 2,025 | FY2025 Results |
| Medical aesthetics R&D reallocation | Raise medical aesthetics to 60% of total R&D budget over three years; focus on regenerative materials, recombinant collagen, weight-loss aesthetics, high-end boosters | 2026–2028 | FY2025 Results |
| Channel targets | Cover 8,500 compliant institutions (already exceeded 9,000 by H1 2026); KA team; public-hospital team; "Spark Plan" for lower tiers; "One Hospital, One Policy" | 2,026 | FY2025 and 2026 Interim Results |
| Marketing 3.0 | Omni-channel marketing; Meituan 618 campaign generated GMV of RMB22m; Xiaohongshu seeding | 2025–2026 | 2026 Interim Results |
| AI-driven R&D | AI aesthetics R&D platform co-built with dProtein (Beijing Shenyuanzhi); AI antibody collaboration with Biocytogen; Xuanzhu AI drug design, TCE and oligonucleotide platforms | 2025–2026 | 2026 Interim Results; Biocytogen release |
| Globalisation | Suisselle investment; Korean subsidiary; US R&D base; EU registrations; expansion into Southeast Asia and Latin America | 2025–2026 | FY2025 and 2026 Interim Results |
| Capitalisation of subsidiaries | Xuanzhu IPO completed; Huisheng "continues to advance its capitalisation process" (possible future listing) | 2025 onward | FY2025 Results |
| Minority buy-in at Meiyan Space | Raised to 90%; intention to acquire remaining interest | H1 2026 onward | 2026 Interim Results |
| Generic divestment | Orderly divestment of underperforming generic and non-core assets | Ongoing | FY2025 and 2026 Interim Results |
| Shareholder returns | Buybacks (HK$500m programme announced Oct 2024; 46m shares repurchased H1 2026); employee share award scheme; dividends resumed | 2024–2026 | HKEX announcements |
Medium-term targets and guidance
No quantitative revenue, margin or earnings guidance has been published. Qualitative targets include: annual launch of new aesthetics products; Semaglutide diabetes approval in early 2027 and an obesity NDA in Q4 2026; Dirozalkib NRDL inclusion in 2026; and Huisheng "significant growth within the next five years" (FY2025 Results). ESG/sustainability targets are not disclosed in the sources reviewed.
Products & Services
Medical aesthetics (Meiyan Space / Meifu Space)
| Product | Category | Description / specifications | Origin | Approval / launch | Positioning / target | Source |
|---|---|---|---|---|---|---|
| Letybo® | Botulinum toxin type A | 900kDa complex, 99.5% purity; 50U and 100U; near-neutral pH; indications include dynamic wrinkles, facial contouring, leg/shoulder slimming. 2025 sales exceeded 1.2m vials (+50%+); 8,000+ institutions | In-licensed from Hugel (Korea); exclusive China partner | NMPA approval 2020; launch 2021; registration renewed to end-2030 | "Light-luxury" price band between imported premium and domestic value toxins; channel traffic driver | FY2025 Results; HKEX 27 Sep 2024 |
| Huiyanzhen | PLLA regenerative filler | Poly-L-lactic acid microspheres for moderate-to-severe nasolabial folds; shallow collagen regeneration and maintenance | Self-developed | Approved Apr 2025; launched Jul 2025; six additional specs approved Jan 2026 (45–150mg range) | Mid-to-high end; cross-sell with full category | FY2025 and 2026 Interim Results |
| Sifuyan | PLLA regenerative filler (large particle) | Deep facial volumetric filling | Self-developed | Approved Apr 2025; launched Jul 2025 | High-net-worth clients at premium institutions; key 2026 priority | 2026 Interim Results |
| Qingyan | PCL regenerative filler | Polycaprolactone microspheres in gel carrier; pre-filled syringe; immediate fill plus collagen stimulation; effect over one year | Group product (origin not specified) | Approved Mar 2025; launched Jul 2025 | Mid-face lifting; high-end anti-ageing courses | FY2025 and 2026 Interim Results |
| Dongyan | Skin booster / rejuvenating serum | Composite solution: sodium hyaluronate, L-carnosine, vitamin B2, collagen amino acids; first approved L-carnosine composite booster for direct facial use | Self-developed | Approved Sep 2025; launched Nov 2025; 1,000+ institutions by H1 2026 | Traffic SKU for new-customer acquisition | FY2025 and 2026 Interim Results |
| Persnica™ | High-G HA filler | Bone-support contour sculpting; sold only as part of combination therapy, not retailed alone | In-licensed (Hugel) | — | Accompanying product in "contour fixation" courses | 2026 Interim Results; HKEX 27 Sep 2024 |
| CELLBOOSTER® | Skin booster | Swiss brand Suisselle; permanent China agency right via strategic shareholding | In-licensed (Suisselle) | China status not disclosed | Expands booster pipeline | FY2025 Results |
| Sylfirm X | Dual-wave RF microneedle | Continuous plus pulsed wave; bipolar non-insulated electrodes; indications include tightening, acne scars, melasma, hair regrowth; US FDA and Korea KFDA certified | In-licensed/distributed (Korean origin; licensor not named in sources) | Nationwide rollout 2025 | "Basal anti-ageing"; 25–40 age group; ~400 institutions, 100,000+ consumers by Jun 2026 | FY2025 and 2026 Interim Results |
| Combination protocols | Service bundles | "Letybo+", "Magic Youthful Face", "contour fixation + advanced anti-ageing", "Sylfirm X+ Plan" | Proprietary marketing | 2025–2026 | Raise ticket size and loyalty | FY2025 and 2026 Interim Results |
| Semaglutide (weight-loss indication) | GLP-1 | Greater China clinical and commercial rights for the obesity indication licensed to Meiyan Space (2024) | Huisheng-developed | NDA expected Q4 2026 | Weight-management aesthetics | 2026 Interim Results |
Medical aesthetics pipeline (cut-off 31 Jul 2026, 2026 Interim Results): novel regenerative materials (CaHA, PHA etc.) — 4 self-developed plus 2 jointly invested; collagen/silk fibroin (animal, recombinant humanised, recombinant human) — 8 self-developed plus 2 exclusively distributed; HA super boosters (PDRN and composites) — 4 self-developed plus 2 exclusive; HA composites/fillers — 7 self-developed; devices — facial and body ultrasound (2 exclusive), cryolipolysis (1 exclusive), Thermage-type (1 exclusive), fat harvesting system (1 acquired); GLP-1 (1 self-developed). Management cites 40+ candidates on five proprietary technology platforms with 20+ in clinical trials, plus a first-in-class PHA regenerative material. Two high-end composite skin boosters have completed filing dossiers. Meiyan reported over 30 approved products as of Sep 2025 (HKEX, 30 Sep 2025). Pricing is not publicly disclosed for any aesthetics product.
Innovative medicine — Xuanzhu Biopharm (2575.HK)
| Product / candidate | Target / class | Indication(s) | Status (31 Jul 2026) | Commercial data | Source |
|---|---|---|---|---|---|
| Xuan Yue Ning (Bireociclib) | CDK2/4/6 inhibitor, small molecule, in-house | HR+/HER2- advanced breast cancer: later-line monotherapy; 2L with fulvestrant; 1L with AI | Approved May 2025 (two indications); 1L approved Mar 2026; NRDL Dec 2025; adjuvant early BC in development | 500+ hospitals; 140+ sales staff; 200+ DTP pharmacies; BRIGHT-2 final mPFS 17.5 vs 7.3 months (HR 0.47, JAMA Oncology) | FY2025 and 2026 Interim Results |
| Xuan Fei Ning (Dirozalkib) | ALK inhibitor, in-house | 1L ALK+ advanced NSCLC; adjuvant in development | Approved Aug 2025; NRDL targeted for 2026 | ~200 hospitals (end-2025); DIAMOND-2 mPFS 31.3 vs 12.9 months (HR 0.47), IC-ORR 91.7% | FY2025 and 2026 Interim Results |
| An Jiu Wei (Anaprazole Sodium) | Novel PPI, in-house, global IP | Duodenal ulcer (approved); reflux esophagitis (NDA accepted); H. pylori eradication (Ph III started) | Approved Jun 2023; NRDL renewed 2025 at unchanged price | Nearly 2,500 institutions; 90+ distributors | FY2025 and 2026 Interim Results |
| KM602 | CD80 fusion protein (acquired) | Solid tumours (melanoma etc.) | Clinical | — | Pipeline tables |
| KM501 | HER2/HER2 biparatopic ADC (in-house) | HER2+ and HER2-low solid tumours | Clinical | — | Pipeline tables |
| XZP-7797 | PARP1-selective inhibitor | Solid tumours incl. brain metastases | IND Feb 2025; Ph I from Dec 2025 | Partnering talks (US/EU/Japan/Korea) | FY2025 Results |
| XZP-6924 | USP1 inhibitor | Solid tumours | Early clinical/IND | — | Pipeline tables |
| XZB-0004 | AXL inhibitor (licensed-in) | Solid tumours; MDS/AML | Clinical | — | Pipeline tables |
| XZP-6877 | DNA-PK inhibitor | Solid tumours | Early | — | Pipeline tables |
| NG-350A | CD40-expressing oncolytic virus (licensed-in) | Solid tumours; LARC (pMMR) | US FDA Fast Track | — | FY2025 Results |
| XZP-P607 | ENPP3/CD3 bispecific (TCE) | Renal, lung, endometrial cancer | Preclinical (new in 2026) | — | 2026 Interim Results |
| XZP-P608 | KLK5/7–IL4R bispecific | Atopic dermatitis | Preclinical (new in 2026) | — | 2026 Interim Results |
| XZP-5610 | FXR agonist | NASH | Clinical | — | Pipeline tables |
| XZP-6019 | KHK inhibitor | NASH | Early | — | Pipeline tables |
At IPO (Sep 2025), Xuanzhu reported 15 issued China patents and 28 issued patents in the US and other jurisdictions (etnet IPO data).
Innovative and other medicine — Huisheng Biopharm
| Product | Class | Status | Commercial notes | Source |
|---|---|---|---|---|
| Hui You Jing (ganagliflozin proline tablets) | Class 1 SGLT-2 inhibitor; also + metformin | Approved Jan 2024; NRDL 2024 | Exclusive Greater China promotion by Huadong Medicine; 7,000+ hospitals | FY2025 and 2026 Interim Results |
| Hui You Jia (insulin degludec/insulin aspart 70/30) | First domestic biosimilar | Approved Jul 2024 | Exclusive mainland commercialisation by Tonghua Dongbao (from 14 Feb 2026); nearly 6,000 hospitals | FY2025 and 2026 Interim Results |
| Hui You Da (insulin degludec) | First domestic biosimilar; ~42h action | Approved Aug 2024 | Tonghua Dongbao; nearly 900 hospitals; ANVISA (Brazil) GMP certification | FY2025 and 2026 Interim Results |
| Hui You Rui / Rui 30 / Rui 50 | Insulin aspart and premixes | Marketed | — | Pipeline tables |
| Semaglutide injection (diabetes) | GLP-1 RA biosimilar | NDA accepted Aug 2025; passed NMPA on-site inspection; approval expected early 2027 | — | 2026 Interim Results |
| Semaglutide injection (obesity) | GLP-1 RA | Ph III complete; NDA expected Q4 2026 | Greater China rights licensed to Meiyan Space | 2026 Interim Results |
| P052 | GLP-1R/GCGR dual agonist | IND approved | T2D and obesity | FY2025 Results |
| HSP002 | Once-weekly insulin | Development | — | Pipeline tables |
| Insulin degludec/liraglutide | Combination | Development | — | Pipeline tables |
| Ganagliflozin/metformin XR | Combination | Development | — | Pipeline tables |
| Empagliflozin, Dapagliflozin | SGLT-2 generics | Dapagliflozin approved 2025 | — | FY2025 Results |
| Sitagliptin (±metformin), Vildagliptin, Linagliptin | DPP-4 generics | Marketed/approved | — | Pipeline tables |
| Repaglinide | Glinide | Approved H1 2026 (consistency-evaluated) | — | 2026 Interim Results |
| Mecobalamin (tab/inj), Thioctic acid inj., Calcium dobesilate, Epalrestat | Diabetic complications | Marketed | — | Pipeline tables |
As of 31 Jul 2026, Huisheng had 18 approved varieties (27 specifications, 29 marketing approvals) (2026 Interim Results).
Generic medicine (selected)
| Period | New approvals / consistency evaluations | Source |
|---|---|---|
| FY2025 | 11 new products: Sugammadex Sodium Inj., Aspirin EC Tablets, Zoledronic Acid Inj., Duloxetine EC Capsules, Metaraminol Inj., Etomidate MCT/LCT Emulsion, Nicorandil Inj., Levetiracetam Oral Solution, Phloroglucinol Inj., Dipyridamole Tablets, Milrinone Inj. New strengths: Citicoline Sodium Inj., Sacubitril Valsartan Tablets. Consistency evaluation passed: Ornidazole Inj., Edaravone Inj., Nicorandil Tablets | FY2025 Results |
| H1 2026 | 8 approvals, all consistency-evaluated: Pentoxifylline Inj. and SR Tablets, Tirofiban/NaCl Inj., Cefazolin dual-chamber bag, Lopinavir/Ritonavir Tablets (only four domestic approvals), Tedizolid Phosphate for Inj., Vortioxetine Tablets, Cisatracurium Inj. | 2026 Interim Results |
The group holds approvals for nearly 100 generic products in CCV, anti-infective and neurology (FY2025 Results). Historic franchise brands include Kelinao (cinepazide maleate), Anjieli, Chuanqing, Qu'Ao, Aogan, GM1, Oudimei, Yuanzhijiu, Yeduojia and Guhong (Annual Reports 2010–2014); their current revenue contribution is not disclosed.
Financial Narrative
Income statement
Company-reported operating profit was RMB607.1m in FY2025 and a loss of RMB138.1m in FY2024 (FY2025 Results); the gap versus S&P EBIT reflects other income (RMB200.5m) and other gains (RMB60.5m) included by the company. FY2025 DPS comprises an interim dividend of RMB0.99 cents and a final of RMB0.96 cents. FY2024 DPS is the RMB1.90-cent interim (no final). FY2021 company-reported revenue from continuing operations was RMB3,291.3m before later restatement; the S&P figure of RMB3,038m reflects restatement for discontinued operations (FY2021 Results vs S&P).
Margins and growth (%)
Revenue CAGR (derived): FY2021–FY2025 is -3.7% per year; FY2022–FY2025 is +6.3% per year; FY2023–FY2025 is +18.6% per year.
Balance sheet
Negative net debt denotes net cash. Company-reported intangible assets at 31 Dec 2025 were RMB953.8m (deferred development costs RMB518.1m plus product development in progress RMB408.3m), versus S&P's RMB435.6m; S&P appears to reclassify capitalised development costs to long-term deferred charges (RMB518.1m). Company-reported aggregate cash, wealth-management products, pledged and time deposits were RMB4,397.4m (31 Dec 2025) and RMB4,018.2m (30 Jun 2026).
Off-balance-sheet-like obligations: "redemption liabilities on subsidiaries' shares" — repurchase obligations to third-party investors in subsidiaries — generated interest expense of RMB161.8m in FY2025 and RMB228.8m in FY2024 (FY2025 Results). Xuanzhu-related obligations were released at its October 2025 listing, cutting H1 2026 redemption interest to RMB52.9m from RMB87.0m (2026 Interim Results). Remaining obligations (largely Huisheng-related, inferred) were not quantified separately in sources reviewed. Other non-current liabilities fell from RMB1,346.6m to RMB134.9m in FY2025, consistent with the Xuanzhu release.
Cash flow
TTM to 30 Jun 2026: operating cash flow RMB-20.5m; free cash flow RMB-98.7m (S&P).
Ratios (derived from tables above; year-end basis)
ROIC (S&P, TTM Aug 2026) was 5.4% and WACC 9.2% (StockAnalysis). Net debt to EBITDA is negative because of net cash and is meaningless where EBITDA is negative (blank). Cash conversion cycle is not disclosed; the company reported inventory turnover of 221 days for H1 2026 (206 days in H1 2025), and trade receivables are on 90–180 day terms (FY2025 Results). Interest coverage is depressed by non-cash redemption-liability interest.
Commentary on trends, inflections and drivers
Revenue. The FY2021–FY2023 collapse (-39% cumulative) was policy-driven: VBP price cuts and the inclusion of key products in the national key monitoring catalogue crushed the CCV generic franchise, while carve-outs moved businesses into discontinued operations. FY2024 was the trough (+2.2%). FY2025's +37.7% was almost entirely medical aesthetics (+RMB741.1m) partly offset by generics (-RMB143.0m). H1 2026 growth stalled at +1.3% as a RMB296.2m generic decline offset aesthetics (+RMB108.0m) and innovative (+RMB203.2m) gains.
Profitability. Gross margin is mix-driven: it peaked at 80.0% in FY2021 when branded CCV generics dominated, fell with VBP, then recovered to 68.8% in FY2025 on aesthetics (segment gross margin 79.5%). H1 2026 gross margin dropped to 58.7% from 66.1% due to generic list-price adjustments, signalling that generic gross margin has compressed severely. Operating leverage is visible in falling R&D (from RMB936.6m in FY2022 to RMB291.3m in FY2025) as core pipeline assets reached approval and Xuanzhu began to self-fund.
Earnings quality. FY2025 profit before tax of RMB417.2m was achieved despite RMB201.6m of finance costs (80% redemption-liability interest) and a 55.6% tax rate. H1 2026 profit was flattered by a RMB154.2m subsidiary-disposal gain and a RMB110.7m share of associate profit, partly offset by a RMB64.2m impairment of equity-accounted investments. Excluding the disposal gain and associate profit, H1 2026 pre-tax profit would have been roughly RMB101m (derived), well below the RMB156.9m in H1 2025.
Cash generation. The deterioration in operating cash flow to RMB-23.6m in FY2025 despite a return to profit is the most important analytical red flag. Accounts receivable nearly doubled (RMB594m to RMB1,156m) and trade and other receivables rose a further 22.3% to RMB2,372.0m by Jun 2026, including RMB259.9m of loans to third parties and RMB170.1m of loans to associates. Combined with the 27.8% single-customer concentration, this suggests growth is being financed on extended credit to large channel partners.
Balance sheet. Net cash of approximately RMB3.0bn (FY2025) and borrowings-to-equity of 14.9% (Jun 2026) give ample liquidity. All bank borrowings are secured and RMB-denominated (rates 2.55–4.00%). Equity attributable rose RMB1.48bn in FY2025, largely through reserves movements from the Xuanzhu listing (reserves swung from RMB-31.4m to RMB1,531.1m).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key operating entities |
|---|---|---|
Medical aesthetic products | Botulinum toxin, regenerative fillers (PLLA, PCL), HA fillers, skin boosters, optoelectronic devices, body sculpting, skin care | Meiyan Space Biotechnology (Jilin) Co., Ltd. (90% owned after H1 2026); Beijing Meifu Space Medical Equipment Co., Ltd. |
Innovative medicine and other medicine | Innovative oncology, digestive, NASH drugs; diabetes/metabolic drugs; biosimilar insulins | Xuanzhu Biopharmaceutical Co., Ltd. (2575.HK, non-wholly owned); Huisheng Biopharmaceutical Co., Ltd. (non-wholly owned) |
Generic medicine | Nearly 100 generic products: CCV, anti-infective, neurology and others | Legacy Sihuan manufacturing subsidiaries |
Segment revenue (CNY Mn)
| Segment revenue (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical aesthetic products | 149.8 | 449.9 | 744.2 | 1,485.3 |
Innovative medicine and other medicine | 60.9 | — | 57.6 | 176.4 |
Generic medicine | — | 1,398.8 | 1,099.3 | 956.3 |
Group total | 2,181 | 1,860.5 | 1,901.1 | 2,618.0 |
Revenue by Segment
| Segment result (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Medical aesthetic products | 90 | 251.0 | 818.4 |
Innovative medicine and other medicine | — | -948.0 | -648.0 |
Generic medicine | — | 356.5 | 282.6 |
Total segment results | — | -340.5 | 453.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2024 | FY2025 |
|---|---|---|
Medical aesthetics segment margin | 33.7 | 55.1 |
Innovative segment margin | -1,645.8 | -367.3 |
Generic segment margin | 32.4 | 29.6 |
Medical aesthetics share of revenue | 39.1 | 56.7 |
Innovative share of revenue | 3.0 | 6.7 |
Generic share of revenue | 57.8 | 36.5 |
Medical aesthetics revenue growth | 65.4 | 99.6 |
Innovative revenue growth | — | 206.3 |
Generic revenue growth | -21.4 | -13.0 |
Revenue by Segment (Half-Yearly)
| Segment metric (CNY Mn) | H1 2025 | H1 2026 |
|---|---|---|
Medical aesthetics revenue | 585.2 | 693.3 |
Innovative and other revenue | 58.2 | 261.4 |
Generic revenue | 502.7 | 206.5 |
Medical aesthetics segment result | 309.5 | 343.2 |
Innovative and other segment result | -274.3 | 28.4 |
Generic segment result | 168.4 | -74.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 3,038 | 2,181 | 1,861 | 1,901 | 2,618 |
Revenue growth (%) | 23.3 | -28.2 | -14.7 | 2.2 | 37.7 |
Gross profit (CNY Mn) | 2,430 | 1,488 | 1,296 | 1,242 | 1,802 |
SG&A (CNY Mn) | 1,129 | 1,023 | 911 | 1,175 | 1,118 |
R&D expense (CNY Mn) | 868.1 | 936.6 | 577.7 | 473.9 | 291.3 |
Operating income S&P EBIT (CNY Mn) | 676.2 | -536.1 | -140.5 | -389.4 | 476.7 |
EBITDA S&P (CNY Mn) | 931.7 | -229.3 | 40.2 | -189.3 | 642.6 |
Interest expense (CNY Mn) | 117.4 | 211.2 | 269.3 | 274.9 | 201.6 |
Pre-tax income (CNY Mn) | 496.0 | -2,123 | -161.3 | -428.3 | 417.2 |
Income tax (CNY Mn) | 253.1 | 196.8 | 96.4 | 43.3 | 231.8 |
Net income incl minorities (CNY Mn) | 232.8 | -2,283 | -257.7 | -471.5 | 185.4 |
Net income attributable (CNY Mn) | 416.5 | -1,915 | -54.0 | -216.7 | 179.7 |
EPS basic (MYR Bn) | 0.0442 | -0.2052 | -0.0058 | -0.0234 | 0.0197 |
EPS diluted (MYR Bn) | 0.0439 | -0.2052 | -0.0058 | -0.0234 | 0.0197 |
Dividend per share (MYR Bn) | 0.013 | 0.033 | — | 0.019 | 0.0195 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 80.0 | 68.2 | 69.6 | 65.3 | 68.8 |
Operating margin S&P (%) | 22.3 | -24.6 | -7.6 | -20.5 | 18.2 |
EBITDA margin (%) | 30.7 | -10.5 | 2.2 | -10.0 | 24.5 |
Pre-tax margin (%) | 16.3 | -97.3 | -8.7 | -22.5 | 15.9 |
Net margin attributable (%) | 13.7 | -87.8 | -2.9 | -11.4 | 6.9 |
R&D intensity (%) | 28.6 | 42.9 | 31.0 | 24.9 | 11.1 |
Effective tax rate (%) | 51.0 | — | — | — | 55.6 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 14,496 | 12,141 | 11,535 | 10,532 | 11,632 |
Cash and equivalents (CNY Mn) | 5,682 | 3,829 | 3,779 | 3,522 | 3,561 |
Cash plus short-term investments (CNY Mn) | 5,792 | 4,792 | 4,498 | 3,777 | 3,977 |
Short-term debt incl current LTD (CNY Mn) | 200 | 341 | 270 | 169 | 217 |
Long-term debt (CNY Mn) | 845 | 849 | 905 | 714 | 695 |
Total debt incl leases (CNY Mn) | 1,081 | 1,291 | 1,251 | 943 | 972 |
Net debt (CNY Mn) | -4,710 | -3,501 | -3,246 | -2,834 | -3,006 |
Total equity (CNY Mn) | 9,150 | 5,640 | 5,137 | 4,949 | 6,900 |
Equity attributable to owners (CNY Mn) | 8,284 | 4,737 | 4,432 | 4,372 | 5,849 |
Minority interests (CNY Mn) | 866 | 903 | 705 | 577 | 1,051 |
Goodwill (CNY Mn) | 14.2 | 1.9 | 1.9 | 1.9 | 1.9 |
Other intangibles S&P (CNY Mn) | 445.8 | 594.1 | 655.5 | 598.8 | 435.6 |
Working capital (CNY Mn) | 5,240 | 4,017 | 2,097 | 2,407 | 2,963 |
Accounts receivable (CNY Mn) | 779 | 522 | 398 | 594 | 1,156 |
Inventory (CNY Mn) | 715 | 607 | 557 | 417 | 618 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 665.3 | 46.5 | 199.5 | 276.1 | -23.6 |
Capital expenditure (CNY Mn) | -601.0 | -402.5 | -125.4 | -70.7 | -58.4 |
Free cash flow (CNY Mn) | 64.3 | -356.0 | 74.1 | 205.4 | -81.9 |
Purchase of intangibles (CNY Mn) | -124.6 | -187.5 | -170.0 | -109.1 | -136.2 |
Dividends paid (CNY Mn) | -122.9 | -130.6 | -298.6 | -177.1 | -90.9 |
Share buybacks (CNY Mn) | -206.4 | 0 | -33.8 | -20.3 | -188.6 |
Change in working capital (CNY Mn) | -246.5 | 145.4 | 111.1 | 18.7 | -579.5 |
Stock-based compensation (CNY Mn) | 59.4 | 89.7 | 89.1 | 418.0 | 9.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE attributable on year-end equity (%) | 5.0 | -40.4 | -1.2 | -5.0 | 3.1 |
ROA (%) | 1.6 | -18.8 | -2.2 | -4.5 | 1.6 |
Current ratio (x) | 3.09 | 2.59 | 1.51 | 1.73 | 1.80 |
Debt to equity (x) | 0.12 | 0.23 | 0.24 | 0.19 | 0.14 |
Interest coverage EBIT over interest (x) | 5.8 | -2.5 | -0.5 | -1.4 | 2.4 |
Asset turnover (x) | 0.21 | 0.18 | 0.16 | 0.18 | 0.23 |
Net debt to EBITDA (x) | -5.1 | — | -80.7 | — | -4.7 |
Region revenue (CNY Mn)
| Region revenue (CNY Mn) | FY2024 | FY2025 |
|---|---|---|
Chinese mainland | 1,888.5 | 2,604.6 |
United States | 12.6 | 13.1 |
Others | 0 | 0.3 |
Total | 1,901.1 | 2,618.0 |
Segment (FY2025 CNY Mn) Overview
| Segment (FY2025 CNY Mn) | Chinese mainland | United States | Others | Total |
|---|---|---|---|---|
Medical aesthetics | 1,472.2 | 13.1 | 0 | 1,485.3 |
Innovative and other | 176.4 | 0 | 0 | 176.4 |
Generic | 956.0 | 0 | 0.3 | 956.3 |
Region growth (%)
| Region growth (%) | FY2025 | H1 2026 |
|---|---|---|
Chinese mainland | 37.9 | 1.5 |
United States | 4.3 | -34.3 |
Share Price & Returns
| Reference point | Price (HKD) | Source |
|---|---|---|
15 Oct 2025 (repurchase average) | 1.5189 | HKEX 15 Oct 2025 |
31 Jul 2026 | 0.90 | StockAnalysis |
14 Aug 2026 | 0.86 | StockAnalysis |
27 Aug 2026 (repurchase average) | 0.8111 | Tiger Brokers |
2 Oct 2026 | 0.72 | StockAnalysis |
Valuation Multiples
| Multiple | Sihuan, 14 Aug 2026 (StockAnalysis) | Sihuan, 2 Oct 2026 (derived) |
|---|---|---|
Market cap (HKD Bn) | 7.76 | approx. 6.5 |
P/E trailing (x) | 39.2 | approx. 19 (on TTM attributable profit RMB301.8m) |
P/E forward (x) | 9.2 | — |
P/S (x) | 2.66 | approx. 2.2 |
P/B (x) | 1.01 | approx. 0.93 (on Jun 2026 attributable equity RMB6,149m) |
EV/Sales (x) | 1.92 | — |
EV/EBITDA (x) | 7.4 | — |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
DPS declared (MYR Bn) | 0.013 | 0.033 | — | 0.019 | 0.0195 |
Cash dividends paid (CNY Mn) | 122.9 | 130.6 | 298.6 | 177.1 | 90.9 |
Balance Sheet (31 Dec 2025–30 Jun 2026)
| Bank borrowings maturity (CNY Mn) | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|
Within one year | 192.3 | 322.2 |
Two to five years | 383.6 | 279.1 |
Beyond five years | 310.8 | 280.6 |
Total bank borrowings | 886.8 | 881.9 |
Analyst Conclusions
Management guidance
No numerical guidance. Qualitative priorities for H2 2026–2027: grow high-end regenerative and skin-booster sales (Sifuyan + Qingyan combinations; review of two high-end boosters); complete acquisition of the remaining Meiyan Space equity; obtain semaglutide diabetes approval (early 2027) and file the obesity NDA (Q4 2026); secure Dirozalkib NRDL inclusion (2026); expand overseas licensing; continue generic divestments; and sustain buybacks.
Consensus expectations
Consensus is thin. The forward P/E of 9.2x at HK$0.86 (StockAnalysis) implies forward earnings expectations near HK$0.09bn above the current trailing level; this should be treated as a single-analyst estimate.
Bull case
-
Aesthetics compounding with margin expansion: a full-category compliant portfolio already earning a 55% segment margin, with self-developed regenerative products growing in a weak market, could sustain double-digit growth as competitors retrench.
-
Sum-of-the-parts discount: with group market cap near HK$6.5bn, net cash around RMB3.1bn and a listed Xuanzhu stake (Xuanzhu itself valued at approx. HK$4.6bn at HK$8.88 on ~518m shares), the aesthetics business may be implied at a low multiple.
-
Self-help catalysts: Meiyan buy-in, falling R&D, lower redemption interest, generic exit and semaglutide launch could lift attributable profit and normalise the 55% tax rate.
Bear case
-
Growth stall: aesthetics growth slowed to 18.5% just as Imeik and Huadong launched toxins; Letybo® pricing could come under pressure.
-
Cash-flow quality: profits have not converted to cash (FY2025 OCF negative; receivables up 95%; 27.8% single-customer exposure), raising channel-stuffing or credit-risk concerns.
-
Generic drag and one-offs: generics are now loss-making and H1 2026 profit relied on non-recurring gains; underlying pre-tax profit may have declined year on year.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Semaglutide obesity NDA submission | Q4 2026 |
| Dirozalkib NRDL negotiation result | Late 2026 |
| Semaglutide diabetes approval | Early 2027 |
| FY2026 results (aesthetics growth, OCF, receivables, tax rate) | Around March 2027 |
| Remaining Meiyan Space buy-in terms | Unspecified |
| Further generic disposals and receivable collection (RMB136.1m) | Ongoing |
| Huisheng capitalisation / listing plans | Unspecified |
| Customer concentration trend | Each results release |
| Competitive response to new toxin approvals | Ongoing |
Analyst verdict
Sihuan Pharmaceutical has executed one of the more credible strategic pivots among Hong Kong-listed Chinese mid-cap pharma companies. Starting from a CCV generic franchise that lost most of its economic value to VBP and the 2019 key monitoring catalogue, management built a medical aesthetics business that in FY2025 produced RMB818m of segment profit, took meaningful share in a contracting market, and pushed the group back to profit after four loss-making years. It simultaneously crystallised the innovative-drug portfolio through the Xuanzhu IPO, removed the costliest redemption liabilities, and now holds a net cash position equal to roughly half its market capitalisation.
The market's scepticism — shares down about 53% since the October 2025 repurchase — is nonetheless understandable. The FY2025 turnaround did not convert into operating cash flow; receivables nearly doubled, and more than a quarter of revenue came from a single customer group. H1 2026 showed aesthetics growth decelerating to 18.5%, generics swinging to a loss and earnings supported by disposal gains. Competition in botulinum toxins intensifies in 2026, and Sihuan's flagship toxin remains an in-licensed product. Governance history and a founder-dominated board add a persistent discount.
On balance, the investment case is a "show-me" story with asymmetric optionality: the valuation (around 0.9x book and a low implied value for aesthetics after netting cash and the Xuanzhu stake) prices in substantial disappointment, while the next 12 months bring identifiable catalysts in GLP-1 approvals, NRDL access, minority buy-ins and generic exits. The decisive variables are cash conversion and aesthetics growth durability. If FY2026 shows positive operating cash flow, stable customer concentration and aesthetics growth above 15%, a re-rating is plausible. If receivables keep outpacing revenue, the discount is warranted. Our stance is neutral with a positive bias, contingent on cash-flow evidence.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / background | Age (born) | Disclosed compensation (latest available) |
|---|---|---|---|---|
Dr Che Fengsheng | Co-founder, Executive Chairman | Founder since 2001; previously Executive Chairman and CEO at SGX listing; Master of Medicine (Neurology), EMBA | 1,962 | CNY7.00m (Simply Wall St) |
Dr Guo Weicheng | Deputy Chairman and CEO | CEO since 20 Oct 2014; co-founding executive (Executive Deputy Chairman at SGX listing); Master of Medicine (General Surgery) | 1,964 | CNY3.00m, 100% salary (Simply Wall St) |
Ms Miao Guili | Executive Director, Deputy CEO, CFO, Chief Investment Officer | — | 1,974 | — |
Dr Zhang Jionglong | Executive Director | Long-serving director (non-executive at SGX listing) | 1,962 | CNY0.65m (Simply Wall St) |
Ms Chen Yanling | Executive Director, Joint Company Secretary | — | 1,979 | CNY1.77m (Simply Wall St) |
Mr Tsang Wah Kwong | Independent Non-executive Director; Audit Committee chair | Appointed 4 Sep 2013 | — | CNY0.37m |
Dr Zhu Xun | Independent Non-executive Director; Remuneration Committee chair | Appointed 20 Feb 2014 | — | CNY0.37m |
Mr Wang Guan | Independent Non-executive Director; Nomination Committee chair | Appointed 2023 | — | CNY0.20m |
Mr Li Kin Wai | Joint Company Secretary | — | 1,989 | — |
Mr Meng Xianhui | Deputy General Manager | Former executive director at SGX listing | 1,964 | — |
Major Shareholders
| Holder | Stake | Source / note |
|---|---|---|
Dr Che Fengsheng | 5.44% (direct, per aggregator) | — |
Dr Zhang Jionglong | 2.18% | Simply Wall St |
Dr Guo Weicheng | 0.12% | Simply Wall St |
Insiders (aggregate) | 7.85% | StockAnalysis (Aug 2026) |
Institutions (aggregate) | 6.53% | StockAnalysis (Aug 2026) |
Free float | Approx. 3.69bn shares of 9.02bn (41%) | StockAnalysis — implies roughly 59% held by strategic/connected holders |
Treasury shares | 334.2m (3.6% of issued) | 2026 Interim Results |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlap | Note |
|---|---|---|---|
Aesthetics — toxins | AbbVie / Allergan Aesthetics (Botox) | Premium imported toxin | Historically about half of China's legal toxin market (2019, ChemLinked) |
Aesthetics — toxins | Lanzhou Institute of Biological Products (Hengli / CBTX-A) | Domestic value toxin | About 47% share in 2019 (ChemLinked) |
Aesthetics — toxins | Ipsen / Galderma (Dysport) | Imported toxin | Approved in China in 2020 |
Aesthetics — toxins | Imeik Technology (300896.SZ) | Toxin approved Jan 2026; HA, PLLA and regenerative fillers | Largest domestic injectables player |
Aesthetics — toxins | Huadong Medicine / Sinclair (000963.SZ) | Ellansé PCL filler; Retoxin toxin approved 2026 | Direct PCL competitor to Qingyan |
Aesthetics — HA / biomaterials | Bloomage Biotechnology (688363.SH) | HA fillers and skin boosters | — |
Aesthetics — regenerative | Changchun Shengboma and other PLLA makers | PLLA fillers | — |
Aesthetics — devices | Solta (Thermage) and other RF microneedle brands | Optoelectronic | Sihuan distributes a Thermage-type device itself |
Oncology — CDK4/6 | Pfizer (palbociclib), Novartis (ribociclib), Lilly (abemaciclib), Hengrui (dalpiciclib) | Bireociclib | Entrenched incumbents with NRDL coverage |
Oncology — ALK | Roche (alectinib), Pfizer (lorlatinib), Betta (ensartinib) | Dirozalkib | Crowded first-line ALK market |
Digestive — PPI/P-CAB | Generic PPIs; P-CABs (vonoprazan, tegoprazan, keverprazan) | Anaprazole | P-CAB substitution risk |
Diabetes / GLP-1 | Novo Nordisk; Hengrui (henagliflozin); Gan & Lee; Tonghua Dongbao (partner); multiple semaglutide biosimilar developers | Huisheng | Semaglutide biosimilar race is crowded |
Generics | CSPC, Sino Biopharm, Luye Pharma and many VBP bidders | CCV, anti-infective | Price-driven competition |
Peer Comparison FY2025
| Metric | Sihuan FY2025 | Imeik FY2025 | Huadong Medicine FY2025 | Huadong aesthetics segment FY2025 |
|---|---|---|---|---|
Revenue (CNY Mn) | 2,618 | 2,453 | 43,612 | 1,800 |
Revenue growth (%) | 37.7 | -18.9 | 4.1 | -21.5 |
Net profit attributable (CNY Mn) | 179.7 | 1,291 | 3,414 | — |
Net margin (%) | 6.9 | 52.6 | 7.8 | — |
R&D intensity (%) | 11.1 | 10.0 | — | — |



